New drug combo aims to keep High-Risk leukemia in remission before transplant
NCT ID NCT07425782
First seen Mar 11, 2026 · Last updated Apr 24, 2026 · Updated 3 times
Summary
This study tests whether a combination of venetoclax and azacitidine works better than standard chemotherapy as a short-term treatment before a stem cell transplant in adults with high-risk acute myeloid leukemia (AML) who are already in remission. About 216 participants will be randomly assigned to one of the two approaches. The goal is to see if the new combination can prevent the cancer from coming back and improve survival, while also monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.